Cas9

Byaibio

Cas9 is the nuclease component of the crispr cas9 genome-editing system, functioning as an RNA-guided editing enzyme that uses sgrna to direct site-specific DNA cleavage and generate double-stranded breaks at target nucleic acids. It is widely used across genome editing, functional genomics, and emerging gene and cell therapies, but its application is constrained by off target genotoxicity and the need for improved delivery. Recent work highlights delivery formats including Cas9 mRNA/sgRNA in ah lnp for pancreas editing, Cas9 RNP delivery in basic, and sequential intracellular RNP payload delivery, as well as engineering strategies such as fusion to lambda phage exonuclease to improve donor DNA integration. Cas9 has also been used to disrupt the let 7c binding site to upregulate UTRN in Duchenne muscular dystrophy, and it remains the benchmark comparator to crispr cas12a, a versatile alternative with distinct advantages. Literature also emphasizes specificity and translational readiness, including meticulous examination of off-target cleavage sites and broader discussions of Cas9-based therapies in cardiovascular disease, epidermolysis bullosa, reproductive failure, and hematopoietic stem cell editing. Overall, Cas9 is the most prominent CRISPR platform protein, central to precision biotechnology and increasingly evaluated in clinically relevant genome-editing workflows.

Genome editing and mechanism

  • Cas9 is the nuclease component of crispr cas9 and is guided by sgrna to specific genomic loci for precise DNA modification, producing double-stranded breaks. (PMID:40833724)
  • The enzyme’s off-target cleavage sites were meticulously examined to assess specificity, underscoring off target genotoxicity as a key limitation. (PMID:40676395)
  • Cas9 was described as the most prominent CRISPR platform protein, transforming functional genomics and advancing toward clinically evaluated gene and cell therapies. (PMID:41987615)
  • Cas9 was used as the comparator to crispr cas12a, which was presented as a versatile alternative with distinct advantages. (PMID:41783155)

Delivery and engineering

  • Cas9 mRNA and sgRNA were delivered by ah lnp to enable precise and efficient genome editing in the pancreas. (PMID:41741655)
  • Cas9 was delivered as a ribonucleoprotein complex in the basic platform for selection-free efficient knockin of large DNA in primary human T cells. (PMID:41485050)
  • Cas9 was also delivered as an RNP payload in sequential transfection experiments using an acoustic electric microfluidic platform. (PMID:42011634)
  • A codon-optimized lambda phage exonuclease was fused with Cas9 to create overhangs and improve donor DNA integration. (PMID:41973928)

Disease applications and translational studies

  • Cas9-generated indels disrupted the let 7c binding site to upregulate UTRN, supporting a therapeutic strategy for Duchenne muscular dystrophy. (PMID:41877484)
  • Cas9 was discussed in a review of CRISPR-based therapies for epidermolysis bullosa, reflecting its role in inherited skin disease development. (PMID:41731282)
  • Cas9 was included among editing technologies used to disrupt dominant and dispensable disease alleles in a therapeutic genetics framework. (PMID:41929339)
  • Cas9 was used in studies of the HBB FSC 36-37 (-T) mutation locus in hematopoietic stem cells, illustrating application to hemoglobinopathy-related editing. (PMID:40676395)
  • Cas9-based gene editing was also discussed in cardiovascular disease guidance and in reproductive failure/germline genome editing reviews. (PMID:41885675)